PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.
Tânia D F CostaTing ZhuangJulie LorentEmilia TurcoHelene OlofssonMiriam Masia-BalagueMiao ZhaoParisa RabieifarNeil RobertsonRaoul KuiperJonas SjölundMatthias SpiessPablo Hernández-VarasUta RabenhorstPernilla RoswallRan MaXiaowei GongJohan HartmanKristian PietrasPeter D AdamsPaola DefilippiStaffan StrömbladPublished in: Nature communications (2019)
Overcoming cellular growth restriction, including the evasion of cellular senescence, is a hallmark of cancer. We report that PAK4 is overexpressed in all human breast cancer subtypes and associated with poor patient outcome. In mice, MMTV-PAK4 overexpression promotes spontaneous mammary cancer, while PAK4 gene depletion delays MMTV-PyMT driven tumors. Importantly, PAK4 prevents senescence-like growth arrest in breast cancer cells in vitro, in vivo and ex vivo, but is not needed in non-immortalized cells, while PAK4 overexpression in untransformed human mammary epithelial cells abrogates H-RAS-V12-induced senescence. Mechanistically, a PAK4 - RELB - C/EBPβ axis controls the senescence-like growth arrest and a PAK4 phosphorylation residue (RELB-Ser151) is critical for RELB-DNA interaction, transcriptional activity and expression of the senescence regulator C/EBPβ. These findings establish PAK4 as a promoter of breast cancer that can overcome oncogene-induced senescence and reveal a selective vulnerability of cancer to PAK4 inhibition.
Keyphrases
- endothelial cells
- high glucose
- dna damage
- papillary thyroid
- stress induced
- transcription factor
- gene expression
- cell cycle
- cell proliferation
- squamous cell
- genome wide
- metabolic syndrome
- poor prognosis
- climate change
- dna methylation
- type diabetes
- childhood cancer
- cell cycle arrest
- cell free
- single cell
- protein kinase
- circulating tumor cells
- genome wide identification